Will a second wave of Covid-19 send stock markets into a spin?

Published 13-MAY-2020 09:23 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The sharp downturn in the ASX could be the start of a much steeper decline if a lead is taken from the US, particularly regarding the potential for a second wave of COVID-19.

There was a sharp downturn in the US market last night, and with Australian stocks rallying last week as getting back to business became a reality, any sign of a second wave in Australia could have a devastating impact on our market.

Of further concern this week is the release of unemployment data on Thursday.

Even though a substantial increase is expected, the alarming numbers could place downward pressure on our market.

Add China trade wars into the mix, a factor that is being exacerbated by the US’s stance and you have a perfect storm.

As a measure of the tension that is building, the CBOE Volatility Index spiked 20% last night to 33 points, its largest one-day gain since mid-April.

Our market already has some ground to make up after the S&P/ASX 200 index fell 58 points or more than 1% to 5403 points yesterday.

With near-term positive catalysts hard to find, a significant retracement wouldn’t surprise.

This is reflected in the ASX SPI200 futures index which is down 68 points to 5320 points.

24 hours

In the US, even the NASDAQ’s six day stampede came to a halt as warnings from authorities suggested a return to business would be dangerous and quite likely lead to a second wave, the signs of which have disturbingly started to emerge in Wuhan, China.

The index slumped 2% or 190 points to close at 9002 points, giving up about half of the gains that were made over the last five trading days.

The Dow fell 1.9% or 457 points to close at 23,764 points.

The S&P 500 fell 2% or 60 points, closing at 2870 points.

The UK was the only bright spot as it rallied nearly 1% or 55 points to close at 5994 points after breaking through the 6000 point mark earlier in the day.

However, the positive sentiment didn’t rub off on mainland European markets with the DAX closing relatively flat at 10,819 points and the CAC 40 shedding 18 points or 0.4% to close at 4472 points.

All eyes will be on Asian markets today as they will probably provide a guide as to what can be expected in Australia.

Yesterday the Hang Seng moved in similar fashion to the ASX, coming off 1.4% or 356 points to close at 24,245 points.

The Nikkei 225 was more resilient, falling just 24 points or 0.1% to close at 20,366 points.

The Shanghai Composite only came off slightly, closing at 2891 points.

While there was little movement in the gold price overnight, it could come back into the picture today given global volatility.

It is currently sitting just above the US$1700 per ounce mark.

There was weakness in the oil price late in the session with the Brent Crude Oil Continuous Contract falling nearly 2% to close at US$29.47 per barrel.

The Australian dollar was relatively unmoved, fetching just shy of US$0.65.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X